Silence Therapeutics (SLN) Non-Current Deferred Tax Liability (2018 - 2020)

Silence Therapeutics (SLN) has 3 years of Non-Current Deferred Tax Liability data on file, last reported at $33011.3 in Q4 2020.

• For the quarter ending Q4 2020, Non-Current Deferred Tax Liability rose 6.98% year-over-year to $33011.3; the trailing twelve-month figure through Dec 2020 stood at $33011.3 (up 6.98% YoY), and the FY2020 full-year result was $32103.7, up 4.76% from the prior year.
• Non-Current Deferred Tax Liability grew to $33011.3 in Q4 2020, from $30857.4 in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $33011.3 in Q4 2020 to a low of $16728.0 in Q4 2018.
• A 3-year average of $26865.5 and a median of $30857.4 in 2019 frame the typical range for Non-Current Deferred Tax Liability.
• Across the five-year window, Non-Current Deferred Tax Liability surged 84.47% in 2019 and climbed 6.98% in 2020, its largest moves.
• Tracing SLN's Non-Current Deferred Tax Liability over 3 years: stood at $16728.0 in 2018, then soared by 84.47% to $30857.4 in 2019, then rose by 6.98% to $33011.3 in 2020.
• Business Quant data shows SLN's Non-Current Deferred Tax Liability at $33011.3 in Q4 2020, $30857.4 in Q4 2019, and $16728.0 in Q4 2018.